ReviewTherapeutic advances in neurological disorders2020
The potential of lasmiditan in migraine.
Review in Therapeutic advances in neurological disorders, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Review
- Lasmiditan and Different Triptans in Menstrual Migraine: A Bayesian Network Meta-analysis.Pain and therapy · 2025Review
- Hallmarks of primary headache: part 1 - migraine.The journal of headache and pain · 2024Review
- Migraine and Its Treatment from the Medicinal Chemistry Perspective.ACS pharmacology & translational science · 2024Review
- Migraine management for the otolaryngologist.Laryngoscope investigative otolaryngology · 2023Review
- The 5-HTNature reviews. Neurology · 2023Review
- Involvement of the cerebellum in migraine.Frontiers in systems neuroscience · 2022Review
- Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance.The journal of headache and pain · 2021Article
- Care Gaps and Recommendations in Vestibular Migraine: An Expert Panel Summit.Frontiers in neurology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lasmiditan, a highly selective 5-hydroxytryptamine receptor 1F (5-HT
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.